|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1992-1-29
|
|
pubmed:abstractText |
The use of recombinant human erythropoietin (r-HuEPO) corrects the anemia of chronic hemodialysis (HD) patients and improves their quality of life. The role of r-HuEPO in the genesis of graft thrombosis is controversial. A retrospective study was conducted of 46 stable chronic HD patients receiving r-HuEPO. It showed an increase in graft thrombosis in those who received the drug.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0889-7190
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
M274-5
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:1751146-Aged,
pubmed-meshheading:1751146-Arteriovenous Shunt, Surgical,
pubmed-meshheading:1751146-Blood Vessel Prosthesis,
pubmed-meshheading:1751146-Dose-Response Relationship, Drug,
pubmed-meshheading:1751146-Erythropoietin,
pubmed-meshheading:1751146-Female,
pubmed-meshheading:1751146-Graft Occlusion, Vascular,
pubmed-meshheading:1751146-Hematocrit,
pubmed-meshheading:1751146-Humans,
pubmed-meshheading:1751146-Kidney Failure, Chronic,
pubmed-meshheading:1751146-Male,
pubmed-meshheading:1751146-Middle Aged,
pubmed-meshheading:1751146-Polytetrafluoroethylene,
pubmed-meshheading:1751146-Recombinant Proteins,
pubmed-meshheading:1751146-Renal Dialysis,
pubmed-meshheading:1751146-Retrospective Studies,
pubmed-meshheading:1751146-Risk Factors
|
|
pubmed:articleTitle |
Effect of recombinant human erythropoietin on vascular access.
|
|
pubmed:affiliation |
Kraftsow Division of Nephrology, Albert Einstein Medical Center, Philadelphia 19141.
|
|
pubmed:publicationType |
Journal Article
|
